- Release Date: 29/10/13 11:42
- Summary: GENERAL: BLT: New Manufacturing Plant Signals Next Stage of Development
- Price Sensitive: No
- Download Document 3.34KB
BLT 29/10/2013 09:42 GENERAL REL: 0942 HRS BLIS Technologies Limited GENERAL: BLT: New Manufacturing Plant Signals Next Stage of Development Listed company BLIS Technologies Ltd has opened a new manufacturing plant in Dunedin New Zealand where product for its nutritional formulation and retail product business are now being produced. The company is in the process of getting necessary export approvals before the plant becomes fully operational. BLIS is focused on niche human health markets producing probiotics targeted specifically at oral health. The company has already built a business supplying ingredients through its global distributor Novus Nutrition Brands to manufacturers and marketers in North America, Japan, South East Asia, Taiwan and Europe. Its retail business is now being broadened with oral probiotic lozenge formulations being marketed in the Asia Pacific region and in Europe under its own brand, and supplied to other companies for marketing under their brands. Chief executive Dr Barry Richardson said the company's strategy over the past five years has been to work through regulatory processes in key international markets before moving on with this type of manufacturing consolidation to give the company more control of its quality and flexibility in responding to market feedback. "We have done a lot of work on getting regulatory approval which is now coming to fruition so the time was right to develop the plant and establish commercial premises outside of Otago University where the company was formed as a commercialisation of science from within the university. "We now have GRAS approval for the US and have approvals for New Zealand and Australia as well as China." Richardson said regulatory approval is essential for a food ingredients and human health business as it determines market access. "While we would have liked this process to go more quickly, we are beholden to regulators in other countries therefore we have had to be patient and methodical in what we have done." "These are the hard yards and I guess the upside of that, once we have gone through the final part of this process, any competitors who want to enter this market will be faced with the same protracted grind. That gives us time to establish in the market before they could arrive." He says fortunately the company has a sophisticated shareholder base that understands what is required in order to get market access. There is also a growth in shareholders with business connections in China and other key markets able to assist with business development in these sectors. "We targeted opening the plant before a reciprocal visit by senior executives of China's largest pharmacy group next month. We have been working hard on establishing the right market channel in China and so this visit by Sinopharm is an important step on the way." BLIS Technologies focuses on working with benevolent microorganisms found in the oral cavity to protect against harmful bacteria that enter the mouth, which is the gateway to the rest of the body. This is particularly important now that antibiotics have become prevalent as they tend to wipe out good microorganisms alongside the bad ones they are targeting. END For further comment contact: Barry Richardson 021 664 742 For media assistance contact: Del Carlini 021 709 907 End CA:00242953 For:BLT Type:GENERAL Time:2013-10-29 09:42:29
- Forums
- NZX - By Stock
- BLT
- Ann: GENERAL: BLT: New Manufacturing Plant Signal
Ann: GENERAL: BLT: New Manufacturing Plant Signal
Featured News
Add BLT (NZSX) to my watchlist
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online